IELSG Annual Meeting 2026 opens tomorrow in Bellinzona
Institute of Oncology Research
On Friday 6 and Saturday 7 March, Bellinzona will host the Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG). The event will take place at the auditorium of the Cantonal Institute of Economics and Commerce and will bring together international experts, including physicians, researchers and specialists from many countries, to present the results of ongoing studies, discuss new therapeutic strategies and define the scientific priorities for the coming years.
Held regularly since 1998, the annual meeting provides a platform for physicians and scientists from around the world to review ongoing research and explore future collaborative projects. During the meeting, workshops involving chairpersons and investigators of IELSG studies, together with pathology review sessions, foster in-depth discussion on the future management of extranodal lymphomas.
The International Extranodal Lymphoma Study Group (IELSG), managed by the IOR Foundation and chaired by Prof. Franco Cavalli, with Prof. Emanuele Zucca as Scientific Director, was founded in 1998 with the aim of promoting the study of the biology of extranodal lymphomas and improving therapeutic outcomes for patients affected by these diseases.
The group brings together a multidisciplinary and international team of experts, including medical oncologists, haematologists, imaging specialists, pathologists, biologists and biostatisticians, all with strong research experience in lymphoproliferative diseases.
Over the years, IELSG studies have involved more than 300 research centres across Europe, Australia, North America, Latin America and Asia, significantly contributing to advances in patient management. The results of these studies have been published in high-impact medical journals and have helped shape clinical practice worldwide, leading to important improvements in patient survival.
Today, the IELSG network continues to play a key role in the development of new treatment strategies and international collaborative research, demonstrating how scientific cooperation can advance the understanding and treatment of rare and complex diseases.
